Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Account Payables: 2016-2017

Historic Change in Account Payables for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Dec 2017 value amounting to $68,000.

  • Rocket Pharmaceuticals' Change in Account Payables rose 136.76% to $68,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$1.1 million, marking a year-over-year decrease of 2682.93%. This contributed to the annual value of -$1.1 million for FY2017, which is 2682.93% down from last year.
  • As of Q4 2017, Rocket Pharmaceuticals' Change in Account Payables stood at $68,000, which was up 353.33% from $15,000 recorded in Q3 2017.
  • Rocket Pharmaceuticals' Change in Account Payables' 5-year high stood at $856,000 during Q3 2016, with a 5-year trough of -$1.5 million in Q2 2017.
  • Moreover, its 2-year median value for Change in Account Payables was -$85,000 (2016), whereas its average is -$147,750.
  • The largest annual percentage gain for Rocket Pharmaceuticals' Change in Account Payables in the last 5 years was 220.62% (2017), contrasted with its biggest fall of 237.14% (2017).
  • Quarterly analysis of 2 years shows Rocket Pharmaceuticals' Change in Account Payables stood at -$185,000 in 2016, then spiked by 136.76% to $68,000 in 2017.
  • Its Change in Account Payables was $68,000 in Q4 2017, compared to $15,000 in Q3 2017 and -$1.5 million in Q2 2017.